Q2 2023 SAGE Therapeutics Inc Earnings Call Transcript
Good morning, and welcome to Sage Therapeutics business update.
(Operator Instructions)
This call is being webcast live on the Investors and Media section of Sage's website at sagerx.com. This call is the property of Sage Therapeutics and recording, reproduction or transmission of this call without the expressed written consent of Sage Therapeutics is strictly prohibited. Please note that this call is being recorded.
I would now like to introduce Ashley Kaplowitz. Please go ahead.
Good morning, and thank you for joining Sage Therapeutics' conference call to discuss business updates, including the FDA approval of zuranolone now branded in the United States as Zurzuvae as a treatment for results with postpartum depression or PPD.
Before we begin, I encourage everyone to go to the Investor and Media section of our website at sagerx.com, where you can find the press release related to today's call as well as slides that we will be reviewing today. I would like to point out that we will be making forward-looking
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |